Cancer Biology

A chronic signaling TGFb zebrafish reporter identifies immune response in melanoma

1. Haley R Noonan
2. Alexandra M Thornock
3. Julia Barbano
4. Michael E Xifaras
5. Chloe S Baron
6. Song Yang
7. Katherine Koczirka
8. Alicia M McConnell
9. Leonard I Zon

• Curated by eLife

  eLife assessment

  This study presents a valuable enhancer reporter of TGFb signaling in melanoma that has a conserved function in both human cell lines and zebrafish. The reporter data is solid and provides interesting insights into TGFb targets in melanoma. However, the model that macrophages preferentially phagocytose certain subsets of melanoma cells is still incomplete, and more data will be needed before this process is clearly understood.

Reviewed by eLife

Two opposing gene expression patterns within ATRX aberrant neuroblastoma

1. Michael R. van Gerven
2. Linda Schild
3. Jennemiek van Arkel
4. Bianca Koopmans
5. Luuk A. Broeils
6. Loes A. M. Meijs
7. Romy van Oosterhout
8. Max M. van Noesel
9. Jan Koster
10. Sander R. van Hooff
11. Jan J. Molenaar
12. Marlinde van den Boogaard

Reviewed by Review Commons

Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer

1. Jiawen Bu
2. Yixiao Zhang
3. Nan Niu
4. Kewei Bi
5. Lisha Sun
6. Xinbo Qiao
7. Yimin Wang
8. Yinan Zhang
9. Xiaofan Jiang
10. Dan Wang
11. Qingtian Ma
12. Huajun Li
13. Caigang Liu

• Curated by eLife

  eLife assessment

  This study presents a valuable finding that the combined use of pyrotinib with dalpiciclib exhibits better therapeutic efficacy against HER2+/HR+ breast cancer cells. The evidence supporting the claims of the authors is rather solid. The work will be of interest to medical biologists and clinical doctors working on breast cancer.

Reviewed by eLife

ahctf1 and kras mutations combine to amplify oncogenic stress and restrict liver overgrowth in a zebrafish model of hepatocellular carcinoma

1. Kimberly J Morgan
2. Karen Doggett
3. Fansuo Geng
4. Stephen Mieruszynski
5. Lachlan Whitehead
6. Kelly A Smith
7. Benjamin M Hogan
8. Cas Simons
9. Gregory J Baillie
10. Ramyar Molania
11. Anthony T Papenfuss
12. Thomas E Hall
13. Elke A Ober
14. Didier YR Stainier
15. Zhiyuan Gong
16. Joan K Heath

• Curated by eLife

  eLife assessment

  Here, Morgan and colleagues report a novel synthetic lethal interaction between nucleoporin inhibition and KRAS-driven hepatocyte hyperproliferation. The authors show that nucleoporin inhibitor treatment or heterozygosity of nucleoporin genes (ahctf1 and/or ranbp2) suppresses KRAS-driven zebrafish larval liver overgrowth, providing impetus for developing Nup inhibitors as hepatocellular carcinoma treatment. Their data provide insights into the consequences of nucleoporin inhibition in cancer, demonstrating that disrupting ahctf1 decreases proliferation and promotes apoptosis by impairing nuclear pore formation and mitotic spindle assembly through a mechanism that may be at least partially dependent on tp53.

Reviewed by eLife

RAS and PP2A activities converge on epigenetic gene regulation

1. Anna Aakula
2. Mukund Sharma
3. Francesco Tabaro
4. Reetta Nätkin
5. Jesse Kamila
6. Henrik Honkanen
7. Matthieu Schapira
8. Cheryl Arrowsmith
9. Matti Nykter
10. Jukka Westermarck

Reviewed by Review Commons

Osteosarcoma-enriched transcripts paradoxically generate osteosarcoma-suppressing extracellular proteins

1. Kexin Li
2. Qingji Huo
3. Nathan H Dimmitt
4. Guofan Qu
5. Junjie Bao
6. Pankita H Pandya
7. M Reza Saadatzadeh
8. Khadijeh Bijangi-Vishehsaraei
9. Melissa A Kacena
10. Karen E Pollok
11. Chien-Chi Lin
12. Bai-Yan Li
13. Hiroki Yokota

• Curated by eLife

  eLife assessment

  There are no known effective treatments available to date for the treatment of osteosarcomas, the earliest identified bone cancer that can spread to other tissues. In this study, the authors have used novel approaches to identify calreticulin and procollagen C-endopeptidase enhancer (PCOLCE) as osteosarcoma tumor suppressor proteins that inhibit osteosarcoma growth both in animal and in vitro cell culture models. These important findings may provide a basis for the future development of more efficient targeted therapies for the treatment of osteosarcomas.

Reviewed by eLife

Interplay of adherens junctions and matrix proteolysis determines the invasive pattern and growth of squamous cell carcinoma

1. Takuya Kato
2. Robert P Jenkins
3. Stefanie Derzsi
4. Melda Tozluoglu
5. Antonio Rullan
6. Steven Hooper
7. Raphaël AG Chaleil
8. Holly Joyce
9. Xiao Fu
10. Selvam Thavaraj
11. Paul A Bates
12. Erik Sahai

• Curated by eLife

  eLife assessment

  This study addresses several gaps that are evident with regards to cancer cell invasion in tissue. The approaches taken by this group encompassing mathematical modeling and experimental procedures are for the most part rigorous. The study is deemed as of high potential impact.

Reviewed by eLife

Low HER2 expression in normal breast epithelium enables dedifferentiation and malignant transformation via chromatin opening

1. Ateequllah Hayat
2. Edward P. Carter
3. Hamish W. King
4. Aysegul Ors
5. Aaron Doe
6. Saul A. Teijeiro
7. Sarah Charrot
8. Susana Godinho
9. Pedro Cutillas
10. Hisham Mohammed
11. Richard P. Grose
12. Gabriella Ficz

Reviewed by Review Commons

EHD2 overexpression promotes tumorigenesis and metastasis in triple-negative breast cancer by regulating store-operated calcium entry

1. Haitao Luan
2. Timothy A Bielecki
3. Bhopal C Mohapatra
4. Namista Islam
5. Insha Mushtaq
6. Aaqib M Bhat
7. Sameer Mirza
8. Sukanya Chakraborty
9. Mohsin Raza
10. Matthew D Storck
11. Michael S Toss
12. Jane L Meza
13. Wallace B Thoreson
14. Donald W Coulter
15. Emad A Rakha
16. Vimla Band
17. Hamid Band

• Curated by eLife

  eLife assessment

  This study, supported by reasonably solid evidence, will be of interest to breast cancer researchers. The finding that EHD2 promotes tumor growth and impacts store-operated calcium entry (SOCE) adds to our understanding of breast cancer cell physiology. If supported by further research, the study provides a rationale for using SOCE inhibitors in a subset of breast cancers, with high expression of EHD2 serving as a potential predictive biomarker for using SOCE inhibitors.

Reviewed by eLife

EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression

1. Zong-Shin Lin
2. Chiao-Chen Chung
3. Yu-Chia Liu
4. Chu-Han Chang
5. Hui-Chia Liu
6. Yung-Yi Liang
7. Teng-Le Huang
8. Tsung-Ming Chen
9. Che-Hsin Lee
10. Chih-Hsin Tang
11. Mien-Chie Hung
12. Ya-Huey Chen

• Curated by eLife

  eLife assessment

  In this study, Hung et al. address the biology and therapy of chondrosarcoma. The authors provided high-quality data that uncovered a new signaling axis, EZH2/hSULF1/c-Met, that promotes chondrosarcoma growth and progress. The authors also reported evidence showing that c-Met inhibition may be a plausible treatment option for chondrosarcoma. The findings are novel and translational and are of interest to cancer biologists and oncologists.

Reviewed by eLife